home > ict > winter 2021 > fast-tracking supply in a patient-centric world
International Clinical Trials

Fast-Tracking Supply in a Patient-Centric World

2020 was a year like no other.

The pandemic brought major disruption to the global clinical trials supply chain, with many studies paused or postponed as a result, and while new vaccines offer some hope, no-one knows exactly how long it will take to bring COVID-19 under control.

What can we learn from the difficult experiences faced over the last 12 months, and how should this guide the approach that pharmaceutical companies take when organising their clinical studies in the future?

This article looks at the possible legacies of the pandemic. It will explore how the challenges faced by pharma companies, particularly around patient recruitment, were successfully met by taking a far more person-centred approach.

It will also look at the potential to speed up operations through new technologies to improve efficiency and the quality of label production and management in a way that balances the demands of accuracy and compliance with the need to deliver quickly

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Richard Adams joined PRISYM ID, a leading provider of regulated content and label management solutions, as CEO, last year. As a leader in the technology and healthcare sector for the past 30 years, he specialises in leveraging innovation to deliver valuable solutions for customers. During his career, Richard has worked at CEO, managing director, and senior vice president levels within EMEA, largely in technology enabled businesses. His sectors of expertise include customer relationship management and online customer engagement for life science, healthcare IT, technology, and digital media. Specialties include leadership, visioning, strategy, and business transformation.
Print this page
Send to a friend
Privacy statement
News and Press Releases

PhoreMost Enters Multi-Project Drug Target Discovery Collaboration With Roche

Cambridge, UK, 06 September 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Roche, one of the world's leading biotechnology companies. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.
More info >>

White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research


Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement